Ruxolitinib phosphate(CAS: 1092939-17-7)

Ruxolitinib phosphate (CAS: 1092939-17-7) is a pharmaceutical compound primarily used as an inhibitor of Janus kinase (JAK) enzymes. It has the chemical formula C21H26N4O9P and is known for its role in treating certain blood disorders, such as myelofibrosis and polycythemia vera. It is a white to off-white solid with good solubility in water and is commonly used in clinical trials and therapeutic applications.

Ruxolitinib phosphate (CAS: 1092939-17-7) is mainly used in the treatment of myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. It functions as a JAK1/JAK2 inhibitor, helping to reduce inflammation and modulate immune responses. Additionally, it is utilized in research for studying JAK-STAT signaling pathways and may have potential applications in other therapeutic areas such as oncology and autoimmune diseases.

Ruxolitinib phosphate (CAS: 1092939-17-7) is considered safe when used as directed in medical and research settings. However, it should be handled with care, and protective measures such as gloves and goggles are recommended to minimize exposure. Safety standards are in place for its use in pharmaceutical applications, and it is subject to regulatory guidelines to ensure proper handling and administration.

Ruxolitinib phosphate (CAS: 1092939-17-7) should be stored in a cool, dry, and dark place, preferably at 2–8°C. It should be kept in a sealed container to prevent moisture exposure and maintain stability. Avoiding prolonged exposure to light and high humidity is essential to preserve its chemical integrity and effectiveness over time.